InxMed Reports Positive Phase Ib/II Data for Ifebemtinib
NANJING, China, Aug 28, 2026 InxMed Co., Ltd. announced the publication in The Lancet Oncology of clinical results evaluating...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NANJING, China, Aug 28, 2026 InxMed Co., Ltd. announced the publication in The Lancet Oncology of clinical results evaluating...
INDIANAPOLIS, U.S., Aug 28, 2026 Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
SOPHIA ANTIPOLIS, FRANCE, Aug 27, 2026 Nicox SA announced that the U.S. Food and Drug Administration (FDA) has accepted...
